Biotech | January 14, 2022
Evonik to build production plant for rhamnolipids in Slovakia
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
